ToxSci Advance Access originally published online on March 28, 2006
Toxicological Sciences 2006 91(2):620-630; doi:10.1093/toxsci/kfj170
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2006.
Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts
* U.S. Public Health Service, Vaccine Production Program, NIH/NIAID/Vaccine Research Center, Bethesda, Maryland 20892-7628; Vaccine Research Center/NIAID/NIH, Bethesda, Maryland 20892; Toxicology Dept., Gene Logic Inc., Gaithersburg, Maryland 20879; Vaccine Production Program/Regulatory Affairs, Vaccine Research Center/NIAID/NIH; Bethesda, Maryland 20892-3011; ¶ Immunology Core Laboratory Section, Vaccine Research Center/NIH/NIAID, Bethesda, Maryland 20892; and || Vaccine Production, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892-3011
Received November 23, 2005; accepted March 17, 2006
The Vaccine Research Center has developed a number of vaccine candidates for different diseases/infectious agents (HIV-1, Severe Acute Respiratory Syndrome virus, West Nile virus, and Ebola virus, plus a plasmid cytokine adjuvant—IL-2/Ig) based on a DNA plasmid vaccine platform. To support the clinical development of each of these vaccine candidates, preclinical studies were performed to screen for potential toxicities (intrinsic and immunotoxicities). All treatment-related toxicities identified in these repeated-dose toxicology studies have been confined primarily to the sites of injection and seem to be the result of both the delivery method (as they are seen in both control and treated animals) and the intended immune response to the vaccine (as they occur with greater frequency and severity in treated animals). Reactogenicity at the site of injection is generally seen to be reversible as the frequency and severity diminished between doses and between the immediate and recovery termination time points. This observation also correlated with the biodistribution data reported in the companion article (Sheets et al., 2006), in which DNA plasmid vaccine was shown to remain at the site of injection, rather than biodistributing widely, and to clear over time. The results of these safety studies have been submitted to the Food and Drug Administration to support the safety of initiating clinical studies with these and related DNA plasmid vaccines. Thus far, standard repeated-dose toxicology studies have not identified any target organs for toxicity (other than the injection site) for our DNA plasmid vaccines at doses up to 8 mg per immunization, regardless of disease indication (i.e., expressed gene-insert) and despite differences (strengths) in the promoters used to drive this expression. As clinical data accumulate with these products, it will be possible to retrospectively compare the safety profiles of the products in the clinic to the results of the repeated-dose toxicology studies, in order to determine the utility of such toxicology studies for signaling potential immunotoxicities or intrinsic toxicities from DNA vaccines. These data build on the biodistribution studies performed (see companion article, Sheets et al., 2006) to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications.
Key Words: DNA vaccines; HIV/AIDS; SARS; WNV; Ebola; DNA vaccine toxicology; plasmid vaccines.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Du, G. Zhao, Y. Lin, H. Sui, C. Chan, S. Ma, Y. He, S. Jiang, C. Wu, K.-Y. Yuen, et al. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection J. Immunol., January 15, 2008; 180(2): 948 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schepp-Berglind, M. Luo, D. Wang, J. A. Wicker, N. U. Raja, B. D. Hoel, D. H. Holman, A. D. T. Barrett, and J. Y. Dong Complex Adenovirus-Mediated Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and Cellular Immune Responses Clin. Vaccine Immunol., September 1, 2007; 14(9): 1117 - 1126. [Abstract] [Full Text] [PDF]
|
|